APM News and Press, Aptorum Group Limited From 09/15/22

Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) a clinical stage biopharmaceutical company dedicated to tackling unmet medical needs in oncology, autoimmune diseases and infectious diseases, is pleased to announce further updates on the analytical and both ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips In general, finding small-cap stocks to buy can be somewhat fraught. These are stocks with market capitalizations between roughly $300 million and $2 billion. They also tend to be riskier than large-cap names. Revenue and...

NEW YORK, Aug. 31, 2022 (GLOBE NEWSWIRE) -- The securities law firm of KlaymanToskes is interested in speaking with current and former customers of Boustead Securities that participated in IPOs offered through the company. Boustead offered IPOs that have since significantly declined in pric...

Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced that Mr. Darren Lui, CEO and Executive Director of Aptorum Group will pr...

NEW YORK, NY and LONDON, UK, and PARIS, FRANCE / ACCESSWIRE / August 19, 2022 / RedChip Companies will air an interview on Aptorum Group Limited (Nasdaq:APM, Euronext Paris:APM) a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseas...

Catalyst Biosciences is highly committed to its cash distribution plan to shareholders of up to $65 million in the near future, with only a $58 million market capitalization. If the proxy contest is cleared up between Catalyst and JDS1 and goes in favor of the executives of Catalyst, ...

The Global Pharmaceutical Industry is Accelerating; Aptorum Group Has Received Orphan Drug Designation from US FDA for Its SACT-1 HONG KONG, July 26, 2022 - (ACN Newswire) - The aging of the population is accelerating, pharmaceutical technology is constantly updating, and the developm...

Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced that Mr. Darren Lui, President and Executive Direct...

Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, is pleased to announce the finalized data from the Phase 1 clinical trial of SACT-1, a repurposed small m...

Aptorum Group press release (NASDAQ:APM): FY GAAP EPS of -$0.71. Revenue of $1.54M (+69.2% Y/Y). For further details see: Aptorum Group GAAP EPS of -$0.71, revenue of $1.54M